Dr. Eric Moore has energized technology transfer (T2) at the U.S. Army Combat Capabilities Development Command Chemical Biological Center (CCDC CBC) since his appointment as director in late 2017. He contributes in-depth understanding of T2 needs from his decades of federal service to counter potential chemical, biological, radiological, nuclear, and explosive (CBRNE) threats to national security and public safety. Prior to this role, Dr. Moore had already built an impressive career of both educational and professional achievements, with a long list of CBRNE-linked activities that undoubtedly inform his deft leadership of the Army laboratory and its technology transfer efforts.
With a Ph.D. in neurophysiology, Dr. Moore began his meritorious federal service in 1992 as a principal investigator on bioweapon countermeasures at the U.S. Army Medical Research Institute of Chemical Defense. Additional positions as director of the Army’s Forensic Toxicology Drug Testing Laboratory, senior officer with the Defense Intelligence Agency, and senior science and technology manager for chemical medical countermeasures in the Defense Threat Reduction Agency (DTRA) preceded his move in 2016 to director of CBC’s Research & Technology Directorate. Collectively, these experiences reinforced Dr. Moore’s commitment to the crucial technology transfer of Army innovations to best achieve field-ready products.
Outside the laboratory, he is highly active among industry and academic stakeholders in CBRNE countermeasures, facilitating the transition of needed CBC technology to commercialization to put better tools in the field more quickly.
Within the Army laboratory, Dr. Moore quickly strengthened technology transfer by establishing CBC’s Strategic Initiatives Group (SIG) to include the Technology Transfer Office. He realigned the SIG to directly report to him, regularly meeting with T2 staff, signing all T2 agreements to remain personally involved, and encouraging CBC technical personnel to engage in T2 activities. Outside the laboratory, he is highly active among industry and academic stakeholders in CBRNE countermeasures, facilitating the transition of needed CBC technology to commercialization to put better tools in the field more quickly.
To promote transfer of CBC innovations and support technology transfer in general, his external T2-related outreach is extensive. He was an invited panel participant at the 2018 Maryland Technology Transfer Summit hosted by the state’s governor and senators. He attended the 2017 FLC Mid-Atlantic regional meeting to acknowledge CBC’s T2 awards. As director, he provides financial support to the CBC ORTA’s promotion and advertising efforts for showcasing CBC technologies at forums and exhibits, publications, social media, and ORTA travel to engage prospective and established T2 partners. To expand CBC’s international T2 presence, Dr. Moore has interacted with RDECOM (now CCDC) Forward Element Centers, the Engineer and Scientist Exchange Program, Data Exchange Agreements, and the Technical Cooperation Program.
On January 30, 2019, Dr. Moore signed CBC’s CRADA agreement with startup MQM Solutions to conduct collaborative research and development in evaluating decontaminant formulations for the neutralization of opioids. A Patent Licensing Agreement executed February 25 granted MQM the use of Army patents 9,724,550 and 9,700,644, both entitled “One Part, Solids Containing Decontamination Blend Composition.” By June, the company sold its first product kit to non-Department of Defense customers, an exceptionally short transition timeframe.
Contact: Dr. Eric Moore, (410) 436-5501, [email protected]